Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.40 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.40 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.40 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.38 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.32 |
| ▸ | AR | P10275 | 1/20 | 0.31 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.31 |
| ▸ | SRC | P12931 | 4/20 | 0.31 |
| ▸ | NAMPT | P43490 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3952737 | 1.00 | CYP1A2 (0.41) | CYP1A2POLBCYP3A4CYP2C19CHRM2 | |
| SCHEMBL8064404 | 0.88 | NR1H2 (0.37) | CYP1A2POLBCYP3A4CYP2C19CHRM2 | |
| SCHEMBL18700391 | 0.87 | CYP1A2 (0.42) | CYP1A2POLBCYP3A4CYP2C19CHRM2 | |
| SCHEMBL1949659 | 0.84 | CYP1A2 (0.44) | CYP1A2POLBCYP3A4CYP2C19CHRM2 | |
| SCHEMBL1439401 | 0.84 | CYP1A2 (0.44) | CYP1A2POLBCYP3A4CYP2C19CHRM2 | |
| SCHEMBL1462675 | 0.84 | CYP1A2 (0.44) | CYP1A2POLBCYP3A4CYP2C19CHRM2 | |
| SCHEMBL1722643 | 0.84 | CYP1A2 (0.44) | CYP1A2POLBCYP3A4CYP2C19CHRM2 | |
| SCHEMBL28995745 | 0.84 | CYP1A2 (0.44) | CYP1A2POLBCYP3A4CYP2C19CHRM2 | |
| SCHEMBL3952274 | 0.84 | ATM (0.36) | RIPK1 | |
| SCHEMBL10238568 | 0.84 | CYP1A2 (0.44) | CYP1A2POLBCYP3A4CYP2C19CHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9505750-B2 | 5-aminocyclylmethyl-oxazolidin-2-one derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2016-11-29 | — | — | US | disclosed |
| EP-2245028-B1 | 5-AMINOCYCLYLMETHYL-OXAZOLIDIN-2-ONE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2012-02-22 | — | — | EP | disclosed |
| US-20110003789-A1 | 5-AMINOCYCLYLMETHYL-OXAZOLIDIN-2-ONE DERIVATIVES | IDORSIA PHARMACEUTICALS LTD (CH) | 2011-01-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110003789-A1 | 5-AMINOCYCLYLMETHYL-OXAZOLIDIN-2-ONE DERIVATIVES | CNKSR1, KCNH1, CBR3 | CYP1A2 808/4885POLB 2386/4885CYP3A4 653/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.